



8/a
Betty
7/14/02
RECEIVED
TECH CENTER 1600/2900
JUL 11 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : P. Kazemi-Esfarjani et al. Art Unit : 1636
Serial No.: 09/639,207 Examiner : S. Pappu
Filed : August 14, 2000
Title : AN ANIMAL MODEL OF POLYGLUTAMINE TOXICITY, METHODS
OF USE, AND MODULATORS OF POLYGLUTAMINE TOXICITY

U.S. Patent and Trademark Office
Arlington, VA 22202

RESPONSE

In response to the action mailed February 28, 2002, the time for responding having been extended to June 28, 2002, by the accompanying fee and petition under 1.136, please amend the application as follows:

In the specification:

The paragraph beginning at page 1, line 20, and bridging to page 2, line 2, has been amended as follows:

--Expansion of polyCAG tracts is associated with human hereditary neurodegenerative disorders and neuronal toxicity (Kaytor *et al.*, *J. Biol. Chem.*, **274**:37507-37510 (1999)). Huntington's disease and several other hereditary neurodegenerative disorders are characterized by expansion of a polyglutamine sequence (LaSpada *et al.*, *Nature*, **352**:77-79 (1991); Koide *et al.*, *Nat. Genet.*, **6**:9-13 (1994); Kawaguchi *et al.*, *Nat. Genet.*, **8**:221-228 (1994); Orr *et al.*, *Nat. Genet.*, **4**:221-226 (1993); Sanpei *et al.*, *Nat. Genet.*, **14**:277-284 (1996); and Zhuchenko *et al.*, *Nat. Genet.*, **15**:62-69 (1997)). The expanded polyCAG tracts encode abnormally long polyglutamine sequences within specific proteins promoting their nuclear and/or cytoplasmic

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

June 26, 2002

Date of Deposit

Lucille M. Bogalle

Signature

Lucille M. Bogalle

Typed or Printed Name of Person Signing Certificate